Waldencast shares surge 22.22% intraday as Obagi Medical drives double-digit growth, FDA approves new filler, and $82.5M Japan trademark sale strengthens balance sheet.

Waldencast surged 22.22% intraday after announcing Q2 2025 results, double-digit growth in Obagi Medical’s Q3 revenue, and strategic milestones. The company highlighted Obagi Medical’s accelerated e-commerce and international sales, FDA approval for Obagi Saypha® MagIQ filler, and the $82.5M sale of the Obagi Japan trademark, which strengthened liquidity. The Novaestiq acquisition expanded its medical aesthetics portfolio, while refinancing efforts reduced leverage. These developments signaled improved operational momentum, balance sheet strength, and long-term growth potential, driving the sharp intraday rally.